203 related articles for article (PubMed ID: 35089089)
1. The Development of
Lee HS; Schwarz SW; Schubert EK; Chen DL; Doot RK; Makvandi M; Lin LL; McDonald ES; Mankoff DA; Mach RH
Radiol Imaging Cancer; 2022 Jan; 4(1):e210070. PubMed ID: 35089089
[TBL] [Abstract][Full Text] [Related]
2. [18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study.
Pantel AR; Gitto SB; Makvandi M; Kim H; Medvedv S; Weeks JK; Torigian DA; Hsieh CJ; Ferman B; Latif NA; Tanyi JL; Martin LP; Lanzo SM; Liu F; Cao Q; Mills GB; Doot RK; Mankoff DA; Mach RH; Lin LL; Simpkins F
Clin Cancer Res; 2023 Apr; 29(8):1515-1527. PubMed ID: 36441795
[TBL] [Abstract][Full Text] [Related]
3. Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts.
Laird J; Lok BH; Carney B; Kossatz S; de Stanchina E; Reiner T; Poirier JT; Rudin CM
J Thorac Oncol; 2019 Oct; 14(10):1743-1752. PubMed ID: 31195178
[TBL] [Abstract][Full Text] [Related]
4. In vivo visualization of PARP inhibitor pharmacodynamics.
McDonald ES; Pantel AR; Shah PD; Farwell MD; Clark AS; Doot RK; Pryma DA; Carlin SD
JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33884961
[TBL] [Abstract][Full Text] [Related]
5. PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First In-Human Studies.
Michel LS; Dyroff S; Brooks FJ; Spayd KJ; Lim S; Engle JT; Phillips S; Tan B; Wang-Gillam A; Bognar C; Chu W; Zhou D; Mach RH; Laforest R; Chen DL
Radiology; 2017 Feb; 282(2):453-463. PubMed ID: 27841728
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, and Evaluation of [
Zheng W; Huang Y; Xie Y; Yang T; Cheng X; Chen H; Li C; Jiang Z; Yu Z; Li Z; Zhang L; Yuan L; Liu Y; Liang Y; Wu Z
Mol Pharm; 2024 May; 21(5):2606-2621. PubMed ID: 38606716
[TBL] [Abstract][Full Text] [Related]
7. Molecular imaging of PARP in cancer: state-of-the-art.
Filippi L; Urso L; Frantellizzi V; Marzo K; Marzola MC; Schillaci O; Evangelista L
Expert Rev Mol Diagn; 2023; 23(12):1167-1174. PubMed ID: 38009232
[TBL] [Abstract][Full Text] [Related]
8. PARP-1 Expression Quantified by [
Sander Effron S; Makvandi M; Lin L; Xu K; Li S; Lee H; Hou C; Pryma DA; Koch C; Mach RH
Cancer Biother Radiopharm; 2017 Feb; 32(1):9-15. PubMed ID: 28118040
[TBL] [Abstract][Full Text] [Related]
9. Kinetic and Static Analysis of Poly-(Adenosine Diphosphate-Ribose) Polymerase-1-Targeted
Young AJ; Pantel AR; Viswanath V; Dominguez TL; Makvandi M; Lee H; Li S; Schubert EK; Pryma DA; Farwell MD; Mach RH; Simpkins F; Lin LL; Mankoff DA; Doot RK
J Nucl Med; 2022 Jan; 63(1):44-50. PubMed ID: 33863820
[TBL] [Abstract][Full Text] [Related]
10. An
Zmuda F; Blair A; Liuzzi MC; Malviya G; Chalmers AJ; Lewis D; Sutherland A; Pimlott SL
J Med Chem; 2018 May; 61(9):4103-4114. PubMed ID: 29630818
[TBL] [Abstract][Full Text] [Related]
11. Pilot Study: PARP1 Imaging in Advanced Prostate Cancer.
Dehdashti F; Reimers MA; Shoghi KI; Chen DL; Luo J; Rogers B; Pachynski RK; Sreekumar S; Weimholt C; Zhou D
Mol Imaging Biol; 2022 Dec; 24(6):853-861. PubMed ID: 35701722
[TBL] [Abstract][Full Text] [Related]
12. Two experts and a newbie: [
Stotz S; Kinzler J; Nies AT; Schwab M; Maurer A
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):834-846. PubMed ID: 34486071
[TBL] [Abstract][Full Text] [Related]
13. Veliparib: a new therapeutic option in ovarian cancer?
Ghisoni E; Giannone G; Tuninetti V; Genta S; Scotto G; Aglietta M; Sangiolo D; Mittica G; Valabrega G
Future Oncol; 2019 Jun; 15(17):1975-1987. PubMed ID: 31074636
[TBL] [Abstract][Full Text] [Related]
14. Poly(ADP-ribose) polymerase inhibitor therapeutic effect: are we just scratching the surface?
Hottiger MO
Expert Opin Ther Targets; 2015; 19(9):1149-52. PubMed ID: 26212149
[TBL] [Abstract][Full Text] [Related]
15. Poly-ADP-ribose polymerase (PARP) inhibitors and ovarian function.
Li J; Li Q; Zhang L; Zhang S; Dai Y
Biomed Pharmacother; 2023 Jan; 157():114028. PubMed ID: 36410122
[TBL] [Abstract][Full Text] [Related]
16. Preliminary evaluation of a novel
Zhou D; Xu J; Mpoy C; Chu W; Kim SH; Li H; Rogers BE; Katzenellenbogen JA
Nucl Med Biol; 2018 Nov; 66():26-31. PubMed ID: 30195072
[TBL] [Abstract][Full Text] [Related]
17. [
Shuhendler AJ; Cui L; Chen Z; Shen B; Chen M; James ML; Witney TH; Bazalova-Carter M; Gambhir SS; Chin FT; Graves EE; Rao J
Bioconjug Chem; 2019 May; 30(5):1331-1342. PubMed ID: 30973715
[TBL] [Abstract][Full Text] [Related]
18. A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.
Li Y; Liu CF; Rao GW
Curr Med Chem; 2021; 28(8):1565-1584. PubMed ID: 32164505
[TBL] [Abstract][Full Text] [Related]
19. Solid phase radiosynthesis of an olaparib derivative using 4-[
Xu J; Chen H; Rogers BE; Katzenellenbogen JA; Zhou D
Nucl Med Biol; 2022; 114-115():65-70. PubMed ID: 36193598
[TBL] [Abstract][Full Text] [Related]
20. Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.
Guo Q; Yang Q; Li J; Liu G; Nikoulin I; Jia S
Curr Pharm Biotechnol; 2018; 19(14):1114-1121. PubMed ID: 30585545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]